Live Quote · NASDAQKPTIHealthcare· Biotechnology

Karyopharm Therapeutics Inc.

$9.60 0.52%(+$0.05)
TickerSpark Score
67/100
Solid
93
Valuation
60
Profitability
25
Growth
56
Health
100
Momentum

Built from real-time financials, refreshed daily. For a full Analyst Grade with bull/bear case, price targets, and qualitative risk analysis, generate a KPTI research report →

52-Week Range81% of range
Low
$3.65
Current
$9.60
High
$10.99
Company Overviewwww.karyopharm.com

About the company

Karyopharm Therapeutics Inc. is a pharmaceutical company that has already brought products to market, focusing on identifying, advancing, and selling medications designed to disrupt nuclear export pathways. These drugs are primarily aimed at treating cancer and various other illnesses.

CEO
Richard A. Paulson
IPO
2013
Employees
279
HQ
Newton, MA, US

Price Chart

+108.24% · this period
$10.21$6.99$3.77Jul 02Dec 31Jul 02
Valuation
Market Cap
$217.56M
P/E
-0.65
P/S
1.44
P/B
-0.80
EV/EBITDA
-2.42
Div Yield
0.00%
Profitability
Gross Margin
96.03%
Op Margin
-55.73%
Net Margin
-129.02%
ROE
73.11%
ROIC
-177.79%
Growth & Income
Revenue
$146.07M · 0.57%
Net Income
$-196,039,000 · -156.52%
EPS
$-17.93 · -90.54%
Op Income
$-90,707,000
FCF YoY
40.95%
Performance & Tape
52W High
$10.99
52W Low
$3.65
50D MA
$8.95
200D MA
$7.42
Beta
0.81
Avg Volume
493.28K

Get TickerSpark's AI analysis on KPTI

Create an account to generate AI analysis on any ticker — technical setup, analyst consensus, earnings watch, insider pulse, financial health, and peer context. Ready in about a minute.

Get Pro Access →

Already have an account? Log in

Form 4 · Filings

Recent insider transactions

Who's buying, who's selling, and how much.

DateInsiderTypeShares
May 21, 26Oliger Christy J.other15,508
May 21, 26PAKIANATHAN DEEPIKAother15,508
May 21, 26Schor Chenother15,508
May 21, 26Su Zhenother15,508
May 21, 26BOHLIN GAREN Gother15,508
May 21, 26Greene Barry Eother15,508
May 13, 26Poulton Stuartother896
May 14, 26Poulton Stuartsell403
May 13, 26Rangwala Reshmaother947
May 14, 26Rangwala Reshmasell408
Coverage · KPTI

Our KPTI coverage

Recent articles, reports, and earnings notes.

On-Demand Research

No research on KPTI yet

For a full analyst-grade research report — grades, price targets, financials, chart analysis — generate one on demand.

Generate KPTI report →
Internal Compare

Similar companies

Peers in the same neighborhood.